Pop­u­la­tion phar­ma­co­ki­net­ics: Drug­mak­ers seek clar­i­ty and ad­di­tions to re­vised FDA guid­ance

About a dozen drug­mak­ers and in­dus­try groups re­cent­ly of­fered their opin­ions on a re­vised FDA draft guid­ance re­lat­ed to pop­u­la­tion phar­ma­co­ki­net­ics (PK) analy­ses sub­mit­ted as part of new drug ap­pli­ca­tions and bi­o­log­ic li­cense ap­pli­ca­tions.

The com­ments large­ly seek spe­cif­ic tweaks to the 23-page re­vised draft, which was re­leased in Ju­ly, al­though some of the com­ments al­so seek fur­ther clar­i­ty and new ad­di­tions to the guid­ance.

In­dus­try group PhRMA, for in­stance, rec­om­mends that the FDA add more spe­cif­ic ex­am­ples or lit­er­a­ture ref­er­ences through­out “to pro­vide de­tail to the high-lev­el rec­om­men­da­tions and to sup­port the tech­ni­cal state­ments.” The FDA al­so should pro­vide spe­cif­ic ex­am­ples of where pop­u­la­tion PK da­ta may al­le­vi­ate the need for a post­mar­ket­ing re­quire­ment or post­mar­ket­ing com­mit­ment, PhRMA says.

Bay­er, mean­while, takes is­sue with the FDA’s in­clu­sion of an ex­ec­u­tive sum­ma­ry in the pop­u­la­tion PK re­port that should fo­cus on the key find­ings af­fect­ing ap­proval or la­bel de­ci­sion or any oth­er rec­om­men­da­tion based on the pop­u­la­tion PK analy­sis.

“Al­though Bay­er agrees that an ex­ec­u­tive sum­ma­ry could be ben­e­fi­cial, the pop­u­la­tion PK re­port is not the cor­rect place. Clin­i­cal in­ter­pre­ta­tion and la­bel de­ci­sion re­quire, in gen­er­al, an as­sess­ment of the all of the da­ta e.g. the re­sult of ex­po­sure re­sponse analy­sis and clin­i­cal safe­ty and ef­fi­ca­cy re­sults of the piv­otal study needs to be avail­able. Very of­ten pop­u­la­tion PK mod­els are de­vel­oped at dif­fer­ent stages of drug de­vel­op­ment and re­port­ed ear­li­er,” Bay­er adds.

The com­pa­ny al­so rais­es the con­cern that the struc­ture of the re­port will not be aligned with the Eu­ro­pean Med­i­cines Agency and Japan’s PM­DA guide­line, as well as the gen­er­al struc­ture of clin­i­cal re­ports.

In ad­di­tion, Astel­las seeks fur­ther specifics from the FDA, not­ing that the draft in­cludes “sub­jec­tive and non-quan­ti­ta­tive terms,” such as “ad­e­quate,” “suf­fi­cient,” “rel­e­vant” and “nar­row.”

“While we ap­pre­ci­ate that the Agency means for the guid­ance to be flex­i­bly in­ter­pret­ed, more quan­ti­ta­tive terms or sug­gest­ed ranges would be ap­pre­ci­at­ed,” Astel­las says.

Pfiz­er pro­pos­es adding a new sec­tion to the draft, ti­tled: “A. Scope of Da­ta for In­clu­sion in Pop­u­la­tion PK Analy­sis” to dis­cuss the use of da­ta from healthy vol­un­teer tri­als “to sup­port the struc­tur­al mod­el and aid com­par­i­son be­tween dif­fer­ent pop­u­la­tions be­fore the cur­rent sec­tion A on study sub­jects and co­vari­ates.”

And Re­gen­eron, among oth­er com­ments, rec­om­mends re­struc­tur­ing the rec­om­men­da­tions for the as­sess­ment of the ef­fects of co­vari­ates “such that all dis­cus­sions are pooled in­to a ded­i­cat­ed sec­tion spe­cif­ic to this top­ic. Such a sec­tion will pro­vide Spon­sors with a clear and con­cise re­source to guide the writ­ing of this com­po­nent of the pop­u­la­tion PK re­port in prepa­ra­tion for ap­ply­ing for mar­ket­ing au­tho­riza­tion.”

Com­ments


RAPS: First pub­lished in Reg­u­la­to­ry Fo­cus™ by the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety, the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care prod­ucts. Click here for more in­for­ma­tion.

Pablo Legorreta, founder and CEO of Royalty Pharma AG, speaks at the annual Milken Institute Global Conference in Beverly Hills, California (Patrick T. Fallon/Bloomberg via Getty Images)

Cap­i­tal­iz­ing Pablo: The world’s biggest drug roy­al­ty buy­er is go­ing pub­lic. And the low-key CEO di­vulges a few se­crets along the way

Pablo Legorreta is one of the most influential players in biopharma you likely never heard of.

Over the last 24 years, Legorreta’s Royalty Pharma group has become, by its own reckoning, the biggest buyer of drug royalties in the world. The CEO and founder has bought up a stake in a lengthy list of the world’s biggest drug franchises, spending $18 billion in the process — $2.2 billion last year alone. And he’s become one of the best-paid execs in the industry, reaping $28 million from the cash flow last year while reserving 20% of the cash flow, less expenses, for himself.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,900+ biopharma pros reading Endpoints daily — and it's free.

Ab­b­Vie wins an ap­proval in uter­ine fi­broid-as­so­ci­at­ed heavy bleed­ing. Are ri­vals My­ovant and Ob­sE­va far be­hind?

Women expel on average about 2 to 3 tablespoons of blood during their time of the month. But with uterine fibroids, heavy bleeding is typical — a third of a cup or more. Drugmakers have been working on oral therapies to try and stem the flow, and as expected, AbbVie and their partners at Neurocrine Biosciences are the first to make it across the finish line.

Known chemically as elagolix, the drug is already approved as a treatment for endometriosis under the brand name Orilissa. It targets the GnRH receptor to decrease the production of estrogen and progesterone.

Sanofi brings in 4 new ex­ec­u­tives in con­tin­ued shake-up, as vac­cines and con­sumer health chief head out the door

In the middle of Sanofi’s multi-pronged race to develop a Covid-19 vaccine, David Loew, the head of their sprawling vaccines unit, is leaving – part of the final flurry of moves in the French giant’ months-long corporate shuffle that will give them new-look leadership under new CEO Paul Hudson.

The company also said today that Alan Main, the head of their consumer healthcare unit, is out, and they named 4 executives to fill new or newly vacated positions, 3 of whom come from both outside both Sanofi and from Pharma.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,900+ biopharma pros reading Endpoints daily — and it's free.

As­traZeneca trum­pets the 'mo­men­tous' da­ta they found for Tagris­so in an ad­ju­vant set­ting for NSCLC — but many of the ex­perts aren’t cheer­ing along

AstraZeneca is rolling out the big guns this evening to provide a salute to their ADAURA data on Tagrisso at ASCO.

Cancer R&D chief José Baselga calls the disease-free survival data for their drug in an adjuvant setting of early stage, epidermal growth factor receptor-mutated NSCLC patients following surgery “momentous.” Roy Herbst, the principal investigator out of Yale, calls it “transformative.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,900+ biopharma pros reading Endpoints daily — and it's free.

Dan O'Day, Gilead CEO (Andrew Harnik, AP Images)

UP­DAT­ED: Gilead leas­es part­ner rights to TIG­IT, PD-1 in a $2B deal with Ar­cus. Now comes the hard part

Gilead CEO Dan O’Day has brokered his way to a PD-1 and lined up a front row seat in the TIGIT arena, inking a deal worth close to $2 billion to align the big biotech closely with Terry Rosen’s Arcus. And $375 million of that comes upfront, with cash for the buy-in plus equity, along with $400 million for R&D and $1.22 billion in reserve to cover opt-in payments and milestones..

Hotly rumored for weeks, the 2 players have formalized a 10-year alliance that starts with rights to the PD-1, zimberelimab. O’Day also has first dibs on TIGIT and 2 other leading programs, agreeing to an opt-in fee ranging from $200 million to $275 million on each. There’s $500 million in potential TIGIT milestones on US regulatory events — likely capped by an approval — if Gilead partners on it and the stars align on the data. And there’s another $150 million opt-in payments for the rest of the Arcus pipeline.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,900+ biopharma pros reading Endpoints daily — and it's free.

Paul Hudson, Sanofi CEO (Getty Images)

Sanofi CEO Paul Hud­son has $23B burn­ing a hole in his pock­et. And here are some hints on how he plans to spend that

Sanofi has reaped $11.1 billion after selling off a big chunk of its Regeneron stock at $515 a share. And now everyone on the M&A side of the business is focused on how CEO Paul Hudson plans to spend it.

After getting stung in France for some awkward politicking — suggesting the US was in the front of the line for Sanofi’s vaccines given American financial support for their work, versus little help from European powers — Hudson now has the much more popular task of managing a major cash cache to pull off something in the order of a big bolt-on. Or two.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,900+ biopharma pros reading Endpoints daily — and it's free.

Roger Perlmutter, Merck R&D chief (YouTube)

Backed by BAR­DA, Mer­ck jumps in­to Covid-19: buy­ing out a vac­cine, part­ner­ing on an­oth­er and adding an­tivi­ral to the mix

Merck execs are making a triple play in a sudden leap into the R&D campaign against Covid-19. And they have more BARDA cash backing them up on the move.

Tuesday morning the pharma giant simultaneously announced plans to buy an Austrian biotech that has been working on a preclinical vaccine candidate, added a collaboration on another vaccine with the nonprofit IAVI and inked a deal with Ridgeback Biotherapeutics on an early-stage antiviral.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,900+ biopharma pros reading Endpoints daily — and it's free.

Bris­tol My­ers Squibb fi­nal­ly gets in the front­line NSCLC game dom­i­nat­ed by Mer­ck, adding a sec­ond Op­di­vo/Yer­voy-based op­tion

Bristol Myers Squibb may be trailing Merck and Roche in the checkpoint race to treat frontline cases of non-small cell lung cancer, but as it does, it makes sure to bring its best feet forward.

Just days after scoring a landmark NSCLC approval for Opdivo and Yervoy alone for PD-L1 positive patients, the company said the FDA has also OK’d using the two agents with a limited course of chemo regardless of the biomarker status.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,900+ biopharma pros reading Endpoints daily — and it's free.

As­traZeneca’s $7B ADC suc­ceeds where Roche failed, im­prov­ing sur­vival in gas­tric can­cer

Another day, another win for Enhertu.

The antibody-drug conjugate AstraZeneca promised up-to $7 billion to partner on has had a quite a few months, beginning with splashy results in a Phase II breast cancer trial, a rapid approval and, earlier this month, breakthrough designations in both non-small cell lung cancer and gastric cancer.

Now, at ASCO, the British pharma and their Japanese partner, Daiichi Sankyo, have shown off the data that led to the gastric cancer designation, which they’ll take back to the FDA. In a pivotal, 187-person Phase II trial, Enhertu shrunk tumors in 42.9% of third-line patients with HER2-positive stomach cancer, compared with 12.5% in a control arm where doctors prescribed their choice of therapy. Progression-free survival was 5.4 months for Enhertu compared to 3.5 months for the control.